<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/FAD72F10-05DD-4B4D-89F4-0475C2A79E10"><gtr:id>FAD72F10-05DD-4B4D-89F4-0475C2A79E10</gtr:id><gtr:name>School of Pharmacy</gtr:name><gtr:department>Pharmaceutics</gtr:department><gtr:address><gtr:line1>29-39 Brunswick Square</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1N 1AX</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/FAD72F10-05DD-4B4D-89F4-0475C2A79E10"><gtr:id>FAD72F10-05DD-4B4D-89F4-0475C2A79E10</gtr:id><gtr:name>School of Pharmacy</gtr:name><gtr:address><gtr:line1>29-39 Brunswick Square</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1N 1AX</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/87B34CEC-810C-43E4-A011-C7463CA82979"><gtr:id>87B34CEC-810C-43E4-A011-C7463CA82979</gtr:id><gtr:firstName>Ijeoma</gtr:firstName><gtr:surname>Uchegbu</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=EP%2FK502340%2F1"><gtr:id>C314584E-03DD-4F31-88C5-F842965C508A</gtr:id><gtr:title>Nanoenabled Peptide Pills - Unlocking the Potential of Therapeutic Peptides</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>EP/K502340/1</gtr:grantReference><gtr:abstractText>The poor bioavailability of peptides, nature's own 'drugs', limits their therapeutic application. The molecular envelope technology (MET) delivery platform allows their use as nano-enabled 'Peptide Pills'. The multi-disciplinary 'Peptide Pill' consortium, comprising drug delivery scientists, neuroscientists, physicists, chemical engineers and clinicians, will develop the pain peptide pill METDoloron. It is estimated that 20% of European adults suffer from chronic pain, which is often inadequately controlled by opioids. Additionally opioids can sometimes cause life threatening side effects. METDoloron avoids these problems by targeting a different receptor to currently used opioids, using an endogenous peptide derivative
and is therefore expected to have a significant impact on the large (US$ 50 billion), fragmented, and growing global market for pain therapeutics. The project partners will confirm METDoloron pharmacology, investigate nanoparticle transport mechanisms, establish scale-up and manufacturing processes, and confirm product (GLP) safety thus creating know-how in biophotonics, pain therapy, flow reactor design and nanoparticle processing techniques. First in man clinical trials will commence on conclusion of this project.</gtr:abstractText><gtr:potentialImpactText>OVERALL ECONOMIC AND QUALITY OF LIFE IMPACTS
The main output from this research is a set of protocols, data and materials which will lead to the first in human trials of METDoloron. The launch of METDoloron in Q3 2016 should contribute to the UK's economic competitiveness, as royalties will flow to Nanomerics. Additionally further academia/ business collaborations will follow once Nanomerics' MET technology has been validated in humans. With respect to quality of life improvements METDoloron is expected to provide improved pain therapy for some of the 80% of the world's population that has inadequate access to pain relief.

SPECIFIC PROJECT IMPACTS
In considering the individual work packages and the data that will emerge from the project over 2 years, the expected exploitable outputs arising from the research are as follows: 1) Confirmation of TPLENK/ delta opioid receptor as a drug/target combination, 2) Identification of MET nanoparticle transport mechanism, 3) Confirmation of regulatory strategy, 4) Definition of MET polymer, peptide and nanoparticle product specification, 5) Identification METDoloron CMC criteria 6) Flow process based optimised MET polymer synthesis method (Coflore ACR), 7) Demonstration of Coflore flow process scale up (Coflore ATR), 8) Confirmation of METDoloron safety in two animal models (GLP standard), 9) Methods for cGMP manufacture and clinical outline protocol. These outputs will all impact on drug development, specifically unlocking further
peptide and/ or neuroscience drugs for development, and demonstrate a path to translation.

SKILLS DEVELOPMENT
Staff recruited to the project will be working at the cutting edge of translational research and will develop the confidence to translate their own ideas into new therapeutics later on in their careers. Staff will benefit from working in close collaboration with Depomed and Nanomerics and will gain knowledge on the criteria for product selection. Staff, while acquiring further skills in their specialist area will also achieve an understanding of other areas of the project (e.g. biophotonics staff will acquire knowledge of drug delivery and the reactor technician will gain knowledge of dosage form design requirements). 

PATHWAYS TO IMPACT
Academic project partners, in consultation with the participating companies, will lead the dissemination of the science via high impact publications, peer group focused workshops (e.g. the February 2011 CARS workshop organised at Exeter University by Julian Moger), conference presentations, and web sites (e.g. www.nanomedicines.org). In addition, the dissemination along commercial channels (e.g. partnering events) and knowledge transfer networks (e.g. NanoKTN) will be directed by the participating companies. Nanomerics' technology will profoundly benefit from the pre-clinical de-risking during the project as well as from the scheduled clinical follow-on development (see GANTT chart). Given Depomed's
experience with their drug Gralise, the collaboration between Nanomerics and Depomed does provide a clear route for the clinical development, launch and marketing of METDoloron. The launch of METDoloron is planned for Q3 2016 following Phase I / II trials in 2014 and Phase III trials in 2015. Follow on products (e.g. TSB funded Anti-cancer Peptide Pill) would enter the market after that date.</gtr:potentialImpactText><gtr:fund><gtr:end>2014-10-31</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/798CB33D-C79E-4578-83F2-72606407192C"><gtr:id>798CB33D-C79E-4578-83F2-72606407192C</gtr:id><gtr:name>EPSRC</gtr:name></gtr:funder><gtr:start>2012-08-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>586898</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs><gtr:impactSummaryOutput><gtr:description>The toxicology and scale up findings have allowed the polymer licensing discussions with third parties to begin. We are in licensing discussions with four companies in Q1 2016.</gtr:description><gtr:firstYearOfImpact>2015</gtr:firstYearOfImpact><gtr:id>CD567663-6BBB-4110-81C8-BAF913B38F4F</gtr:id><gtr:impactTypes><gtr:impactType>Economic</gtr:impactType></gtr:impactTypes><gtr:sector>Healthcare</gtr:sector></gtr:impactSummaryOutput></gtr:impactSummaryOutputs><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>A composition of matter is disclosed for delivering drugs.</gtr:description><gtr:id>B00E70C8-4750-4653-B92F-7FFD1E2DCB34</gtr:id><gtr:impact>This technology underpins the UCL spin out company Nanomerics Ltd.</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:patentId>US 8,470,371</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Polymeric micellar clusters</gtr:title></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>A method of delivering hydrophilic drugs to the brain is disclosed.</gtr:description><gtr:id>6E246248-9607-4911-8643-A64F8E1EAF92</gtr:id><gtr:impact>This discovery will enable the delivery of peptides to the brain.</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:patentId>WO/2015/063510 published in 2015</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Delivering hydrophilic drugs to the brain.</gtr:title></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>A patent application protecting the use of peptide self assemblies to deliver peptides to the brain.</gtr:description><gtr:id>3197F198-299E-4466-B046-B7DB37C29FD2</gtr:id><gtr:impact>This intellectual property has been licensed to Nanomerics Ltd.</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:patentId>WO2012004610</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Delivery of hydrophilic peptides</gtr:title></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:keyFindingsOutput><gtr:description>We have designed, developed and manufactured a pain therapeutic (NM0127) which is now ready for clinical trials.</gtr:description><gtr:exploitationPathways>The next stage is to conduct clinical trials on NM0127 in order to translate the preclinical findings to a clinical setting.</gtr:exploitationPathways><gtr:id>2C5C7A6D-C84F-41D8-8B25-539B641D2920</gtr:id><gtr:sectors><gtr:sector>Healthcare</gtr:sector></gtr:sectors></gtr:keyFindingsOutput><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/386A95A2-C763-46F4-B709-3CF59914D18D"><gtr:id>386A95A2-C763-46F4-B709-3CF59914D18D</gtr:id><gtr:title>Label-free imaging of polymeric nanomedicines using coherent anti-stokes Raman scattering microscopy</gtr:title><gtr:parentPublicationTitle>Journal of Raman Spectroscopy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3f627cdabb3ea1aba70f2f394968a38c"><gtr:id>3f627cdabb3ea1aba70f2f394968a38c</gtr:id><gtr:otherNames>Garrett N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/ECB20A9C-9042-475C-A1F9-6EEFF41F26EE"><gtr:id>ECB20A9C-9042-475C-A1F9-6EEFF41F26EE</gtr:id><gtr:title>Nanofiber-based delivery of therapeutic peptides to the brain.</gtr:title><gtr:parentPublicationTitle>ACS nano</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d8b197842ffc5d493c75252f5df92b8f"><gtr:id>d8b197842ffc5d493c75252f5df92b8f</gtr:id><gtr:otherNames>Mazza M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1936-0851</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/3D7D52CE-2E19-4CB9-BF6E-12E553F874FF"><gtr:id>3D7D52CE-2E19-4CB9-BF6E-12E553F874FF</gtr:id><gtr:title>Delivery of peptides to the blood and brain after oral uptake of quaternary ammonium palmitoyl glycol chitosan nanoparticles.</gtr:title><gtr:parentPublicationTitle>Molecular pharmaceutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/dc68e5a8c7a9df2a97b34b49711d3195"><gtr:id>dc68e5a8c7a9df2a97b34b49711d3195</gtr:id><gtr:otherNames>Lalatsa A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1543-8384</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/0EAA05A3-A05B-4A77-A3F7-792ECDECD98E"><gtr:id>0EAA05A3-A05B-4A77-A3F7-792ECDECD98E</gtr:id><gtr:title>A nano-enabled cancer-specific ITCH RNAi chemotherapy booster for pancreatic cancer.</gtr:title><gtr:parentPublicationTitle>Nanomedicine : nanotechnology, biology, and medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/1f3adf5e444fa44cca0ac65260d0e26b"><gtr:id>1f3adf5e444fa44cca0ac65260d0e26b</gtr:id><gtr:otherNames>de la Fuente M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1549-9634</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D162A6D6-BEF7-49CB-AAB9-FC87DEBB4312"><gtr:id>D162A6D6-BEF7-49CB-AAB9-FC87DEBB4312</gtr:id><gtr:title>Exploring uptake mechanisms of oral nanomedicines using multimodal nonlinear optical microscopy.</gtr:title><gtr:parentPublicationTitle>Journal of biophotonics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/74105fff7bbdae8bf7e346e76d6aa721"><gtr:id>74105fff7bbdae8bf7e346e76d6aa721</gtr:id><gtr:otherNames>Garrett NL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1864-063X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/6CB3411B-3851-4B52-B01A-AD12EEB038E4"><gtr:id>6CB3411B-3851-4B52-B01A-AD12EEB038E4</gtr:id><gtr:title>Lomustine Nanoparticles Enable Both Bone Marrow Sparing and High Brain Drug Levels - A Strategy for Brain Cancer Treatments.</gtr:title><gtr:parentPublicationTitle>Pharmaceutical research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f61b9c7f089144cbc8dfc9fb082ee0a4"><gtr:id>f61b9c7f089144cbc8dfc9fb082ee0a4</gtr:id><gtr:otherNames>Fisusi FA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0724-8741</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/0B88D8F5-09D4-4C6C-A8C4-EC50EA21142E"><gtr:id>0B88D8F5-09D4-4C6C-A8C4-EC50EA21142E</gtr:id><gtr:title>Oral particle uptake and organ targeting drives the activity of amphotericin B nanoparticles.</gtr:title><gtr:parentPublicationTitle>Molecular pharmaceutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/693edfb56410666fd45af9f0e19b892b"><gtr:id>693edfb56410666fd45af9f0e19b892b</gtr:id><gtr:otherNames>Serrano DR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1543-8384</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/6C1C1F74-C81D-483B-9622-86A7C6810148"><gtr:id>6C1C1F74-C81D-483B-9622-86A7C6810148</gtr:id><gtr:title>A prodrug nanoparticle approach for the oral delivery of a hydrophilic peptide, leucine(5)-enkephalin, to the brain.</gtr:title><gtr:parentPublicationTitle>Molecular pharmaceutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/dc68e5a8c7a9df2a97b34b49711d3195"><gtr:id>dc68e5a8c7a9df2a97b34b49711d3195</gtr:id><gtr:otherNames>Lalatsa A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1543-8384</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/686DA698-8892-47BE-BE29-47E52F5AAFA3"><gtr:id>686DA698-8892-47BE-BE29-47E52F5AAFA3</gtr:id><gtr:title>Direct in vivo evidence on the mechanism by which nanoparticles facilitate the absorption of a water insoluble, P-gp substrate.</gtr:title><gtr:parentPublicationTitle>International journal of pharmaceutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/12fa35559c5d26e11d34e2f6ae3f24cc"><gtr:id>12fa35559c5d26e11d34e2f6ae3f24cc</gtr:id><gtr:otherNames>Soundararajan R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0378-5173</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/25ABE223-2D20-4B91-BF85-9AFBD978A963"><gtr:id>25ABE223-2D20-4B91-BF85-9AFBD978A963</gtr:id><gtr:title>Efficacy of DOPE/DC-cholesterol liposomes and GCPQ micelles as AZD6244 nanocarriers in a 3D colorectal cancer in vitro model.</gtr:title><gtr:parentPublicationTitle>Nanomedicine (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/905803c776d5bdac0263a961e8c034cd"><gtr:id>905803c776d5bdac0263a961e8c034cd</gtr:id><gtr:otherNames>L?pez-D?vila V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1743-5889</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/1E9CFCD7-E7B4-4E08-8FA2-96E6526A3EBF"><gtr:id>1E9CFCD7-E7B4-4E08-8FA2-96E6526A3EBF</gtr:id><gtr:title>Polymer Based Gene Silencing: In Vitro Delivery of SiRNA.</gtr:title><gtr:parentPublicationTitle>Methods in molecular biology (Clifton, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/42e414290a56c7de31af967bee4866ca"><gtr:id>42e414290a56c7de31af967bee4866ca</gtr:id><gtr:otherNames>Carlos MI</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1064-3745</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/22090892-63D4-4FAF-B6F4-AFC577BFBA81"><gtr:id>22090892-63D4-4FAF-B6F4-AFC577BFBA81</gtr:id><gtr:title>Chitosan amphiphile coating of peptide nanofibres reduces liver uptake and delivers the peptide to the brain on intravenous administration.</gtr:title><gtr:parentPublicationTitle>Journal of controlled release : official journal of the Controlled Release Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/dc68e5a8c7a9df2a97b34b49711d3195"><gtr:id>dc68e5a8c7a9df2a97b34b49711d3195</gtr:id><gtr:otherNames>Lalatsa A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0168-3659</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/17370640-2E41-428B-832D-23A460EEA84A"><gtr:id>17370640-2E41-428B-832D-23A460EEA84A</gtr:id><gtr:title>Claw amphiphiles with a dendrimer core: nanoparticle stability and drug encapsulation are directly proportional to the number of digits.</gtr:title><gtr:parentPublicationTitle>Langmuir : the ACS journal of surfaces and colloids</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6d5327b23e9f4291abab12d79a95bb95"><gtr:id>6d5327b23e9f4291abab12d79a95bb95</gtr:id><gtr:otherNames>Chooi KW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0743-7463</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B4321AA9-68E0-4D0C-BFBF-CE3D23564F1A"><gtr:id>B4321AA9-68E0-4D0C-BFBF-CE3D23564F1A</gtr:id><gtr:title>Imaging cortical vasculature with stimulated Raman scattering and two-photon photothermal lensing microscopy</gtr:title><gtr:parentPublicationTitle>Journal of Raman Spectroscopy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f979db5c8acdde521a1fec670f945fe4"><gtr:id>f979db5c8acdde521a1fec670f945fe4</gtr:id><gtr:otherNames>Moger J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B1E9CD5F-E06B-44DA-934F-D67EDE84822E"><gtr:id>B1E9CD5F-E06B-44DA-934F-D67EDE84822E</gtr:id><gtr:title>Dextran-pegylated microparticles for enhanced cellular uptake of hydrophobic drugs.</gtr:title><gtr:parentPublicationTitle>European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/8ec7f6f67e52e8997e64d318b446f3da"><gtr:id>8ec7f6f67e52e8997e64d318b446f3da</gtr:id><gtr:otherNames>Cassano R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0939-6411</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/5B3810BE-8F14-4F3F-B9F1-7E434B8F91E3"><gtr:id>5B3810BE-8F14-4F3F-B9F1-7E434B8F91E3</gtr:id><gtr:title>Amphiphilic poly(L-amino acids) - new materials for drug delivery.</gtr:title><gtr:parentPublicationTitle>Journal of controlled release : official journal of the Controlled Release Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/dc68e5a8c7a9df2a97b34b49711d3195"><gtr:id>dc68e5a8c7a9df2a97b34b49711d3195</gtr:id><gtr:otherNames>Lalatsa A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0168-3659</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">EP/K502340/1</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects><gtr:researchSubject><gtr:id>E847DD9B-2053-4BC7-97A9-4213B185C968</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Materials sciences</gtr:text></gtr:researchSubject><gtr:researchSubject><gtr:id>6723A70B-A523-40AB-9740-B6AD2A0677B7</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Medical &amp; health interface</gtr:text></gtr:researchSubject></gtr:researchSubjects><gtr:researchTopics><gtr:researchTopic><gtr:id>B30DC286-3309-48E2-A15D-BDF547057A33</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Drug Formulation &amp; Delivery</gtr:text></gtr:researchTopic><gtr:researchTopic><gtr:id>561091A1-9FC9-4508-B1B2-2F3623E1FC9D</gtr:id><gtr:percentage>25</gtr:percentage><gtr:text>Materials Characterisation</gtr:text></gtr:researchTopic><gtr:researchTopic><gtr:id>063026C5-CD0B-48AB-82F3-6359499A95D4</gtr:id><gtr:percentage>25</gtr:percentage><gtr:text>Materials Synthesis &amp; Growth</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>